Skip to content

ayurvedic treatment of amavata (rheumatoid arthritis)

AN OPEN-LABEL RANDOMISED CONTROL CLINICAL TRIAL TO ASSESS THE EFFICACY OF PANCHASAMA CHURNA ALONG WITH MAHARASNADI KWATHA AND SIMHANADA GUGGULU IN THE MANAGEMENT OF PAIN IN AMAVATA (RHEUMATOID ARTHRITIS) AFTER VIRECHANA AND IN SILICO EVALUATION OF PANCHASAMA CHURNA - nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080464
Enrollment
132
Registered
2025-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M069- Rheumatoid arthritis, unspecified

Interventions

None listed

Sponsors

Dr Anju S Raj
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 21 to 60 years wishing to participate in the trial with a diagnosis of rheumatoid arthritis. Includes both seropositive and seronegative cases. Patients having the clinical manifestation of Amavata (RA) according to Ayurvedic classics -Sandhishool (pain), Shotha (swelling), Sparshasahata (tenderness) and Stabdhata (stiffness),Vrishichikadansavata vedana(pain like scorpion sting), Agnimandya (poor digestion) , Aruchi(anorexia), Gaurav(Feeling of heaviness of body),Utsaha Hani(lack of interest),Mukha vairasya(Perverted taste).

Exclusion criteria

Exclusion criteria: patients unwilling to participate pregnant and lactating women Patients with major complications such as extra-articular manifestations are also excluded. Patients with other systemic complications of RA like RHD, Rheumatic fever, pleural pericardial disease. Patients diagnosed with other arthritis like gouty arthritis, tuberculous arthritis, and psoriatic arthritis. patients with poorly controlled diabetes and hypertension patients who is taking medicines for modern ailments

Design outcomes

Primary

MeasureTime frame
Reduction in Universal pain assessmentTimepoint: baseline,after virechana ,4 weeks after virechana

Secondary

MeasureTime frame
Reduction of RA factor, CRP, ESR Improvement in DAS 28 score To provide relief in the cardinal symptoms of Amavata (RA) Improvement in the quality of life of Amavata patients by using SF 36 Timepoint: baseline, 4 weeks after virechana

Countries

India

Contacts

Public ContactDr Anju S Raj

All India Institute of Ayurveda

drrky68@gmail.com09412148437

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026